CLEVELAND, May 13, 2014 /PRNewswire/ -- DATATRAK
International, Inc. (OTCQX: DTRK), the leader in developing
cloud-based, unified eClinical® technologies and
delivering related services for the clinical trials industry, today
announced that its Chairman and CEO, Mr. Laurence P. Birch, will present at the Drexel
Hamilton Micro-Cap Investor Forum on Thursday, May 15th at 3:00
p.m. ET, in New York
City.
"DATATRAK has exciting news to share with the
investor community," said Mr. Birch. "Our unified
eClinical® solutions deliver a differentiated
benefit to the clinical trials industry. The
DATATRAK ONE® unified platform reduces
complexities, delivering time and cost savings and a superior user
experience, all of which lead to better site compliance, better
data, and ultimately a safer trial. And only DATATRAK
offers the unified experience – which is great news for customers
and investors alike."
The DATATRAK ONE® platform is
the technical infrastructure that powers all DATATRAK
products, which can be used in any combination. The inherent
strength of DATATRAK solution is the connectivity to
the platform, providing a single data source, a single sign-on and
a single and user-friendly interface, greatly reducing clinical
trial complexities.
Join DATATRAK Thought Leaders:
- Twitter
- LinkedIn
- SlideShare
- The DATATRAK Blog
Tweet: DATATRAK #unifiedexperience to be presented at upcoming
investor forum http://bit.ly/1mT3HpB
About DATATRAK International,
Inc.
DATATRAK International is a worldwide
technology and services company delivering unified
eClinical® solutions and related services for the
clinical trials industry. DATATRAK built its
multi-component, comprehensive solution on a single, unified
platform and expanded this concept to include services delivery via
DATATRAK's Clinical and Consulting Services group.
The Company delivers a complete portfolio of software products
designed to accelerate the reporting of clinical research data from
sites to sponsors and ultimately regulatory authorities, faster and
more efficiently than loosely integrated technologies. The
DATATRAK ONE® software solution,
deployed worldwide through an ASP or Enterprise Transfer offering,
supports Preclinical and Phase I - Phase IV drug and device studies
in multiple languages throughout the world. DATATRAK
has offices located in Cleveland,
Ohio; Bryan, Texas; and
Cary (RTP), North Carolina.
DATATRAK has established a UK entity to support our
burgeoning European sales activities; DATATRAK
Technologies Limited is a private limited company registered in
England and Wales under number 8870946, registered office:
One New Change, London, EC4M 9AF,
England. For more information,
visit http://www.datatrak.com.
Except for the historical information contained in this press
release, the statements made in this release are forward-looking
statements. These forward-looking statements
are made based on management's expectations, assumptions, estimates
and current beliefs concerning the operations, future results and
prospects of the Company and are subject to uncertainties and
factors which are difficult to predict and, in many instances, are
beyond the control of the Company, and which could cause actual
results to differ materially from those contemplated in these
forward-looking statements. For a list of certain factors that may
cause actual results to differ materially from those contemplated
in these forward looking statements, please see the Company's
report filed with the OTCQX Market on March
14, 2014 announcing its results for the full-year period
ending December 31, 2013. The Company
undertakes no obligation to update publicly or revise any
forward-looking statement whether as a result of new information,
future events or otherwise.
SOURCE DATATRAK International, Inc.